About
About Aclaris Therapeutics, Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Visit company website
5 years, 5 months ago
Aclaris Therapeutics, Inc is currently in a long term uptrend where the price is trading 13.1% above its 200 day moving average.
From a valuation standpoint, the stock is 87.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 165.0.
Aclaris Therapeutics, Inc's total revenue rose by 44.3% to $2M since the same quarter in the previous year.
Its net income has increased by 29.2% to $-13M since the same quarter in the previous year.
Finally, its free cash flow grew by 57.1% to $-9M since the same quarter in the previous year.
Based on the above factors, Aclaris Therapeutics, Inc gets an overall score of 5/5.